Skip to main content

Table 2 Maternal and cord blood folate biomarkers of FASSTT trial participants

From: Effect of continued folic acid supplementation beyond the first trimester of pregnancy on cognitive performance in the child: a follow-up study from a randomized controlled trial (FASSTT Offspring Trial)

  Placebo (n = 33) Folic acid (n = 37) p value
14th GW (pre-intervention)
 Serum folate, nmol/L 48.7 (40.7, 56.7) 45.6 (39.1, 52.1) 0.544
 RBC folate, nmol/L 1109 (846, 1371) 1223 (1025, 1421) 0.312
36th GW (post-intervention)a
 Serum folate, nmol/L 26.0 (18.9, 33.2) 51.1 (43.6, 58.6) < 0.001
 RBC folate, nmol/L 978 (823, 1133) 1834 (1609, 2060) < 0.001
MTHFR 677TT genotype, % 9 16 0.595
Cord bloodb
 Serum folate, nmol/L 71.7 (60.5, 83.0) 99.1 (86.6, 111.6) 0.002
 RBC folate, nmol/L 1535 (1260, 1810) 2177 (1779, 2574) 0.009
MTHFR 677TT genotype, % 14 9 0.914
  1. Continuous measures presented as mean (95% CI) unless otherwise indicated. Continuous measures compared using independent sample t test. Count measures compared using Pearson’s chi-square
  2. aPost-intervention, following supplementation with folic acid (400 μg/d) for 22 weeks in pregnancy
  3. bCord blood collected upon delivery
\